The Provincial Medicines Administration has organized a video conference on quality and safety supervision and on the guarantee of the supply of medicines for the diagnosis and treatment of new coronary pneumonia
On December 19, the Guangdong Provincial Drug Administration held a video conference on the supervision of quality and safety and drug supply related to the diagnosis and treatment of new coronary pneumonia. Fang Wei, deputy director of the provincial Bureau, comrades in charge of relevant drug supervision departments and directly affiliated institutions, comrades in charge of drug supervision of 21 prefectural and municipal market supervision offices in the province, and comrades in charge of 46 key offices of drugs Production companies for the prevention and control of new coronary pneumonias took part in the meeting.
The meeting made arrangements for drug supply assurance related to the diagnosis and treatment of new coronary pneumonia, requesting regulators and enterprises to strengthen communication and coordination, strengthen overall management, and do a good job in the ensure the supply of antipyretic, cough, antivirals, colds and other medicines. All cities should fully understand the production capacity, production and inventory of relevant enterprises and varieties in their jurisdictions, and take multiple measures to guide production companies to expand capacity and increase production in line with market demand , so as to alleviate the problem of shortages and supply cuts as soon as possible. We should also pay attention to our province’s profound heritage and unique advantages in the production of traditional Chinese medicine, recommend the good medicines produced in Guangdong to the masses, and provide the masses with more and better choices. At the same time, it is necessary to focus on strengthening information communication and cooperation with relevant departments, organize research and coordinate to solve the problems and difficulties encountered by enterprises, train a workforce, and jointly serve the overall situation of prevention and of epidemic control.
The meeting stressed that while ensuring supply, we must strictly adhere to the bottom line of ensuring the quality and safety of medicines. Regulatory departments should effectively strengthen the production quality supervision, sampling supervision and inspection, and adverse reaction monitoring of epidemic prevention and control drugs, conduct thorough investigations into hidden risks, and strictly investigate and punish violations of laws and regulations. Enterprises should implement the primary responsibility for quality and safety, strengthen product life cycle quality control, do a good job of resuming production and expanding capacity, and increasing production of key varieties in accordance with laws and regulations and ensure the quality and safety of epidemic prevention and control drug and supply reserves. (Contribution from the Drug Supervision Department of the Provincial Office)
